KRT88P and autoimmune hepatitis: For anti-HBc-positive patients-particularly those without protective anti-HBs or with detectable HBV-DNA-antiviral prophylaxis with agents such as entecavir or tenofovir could be considered as a preventive strategy to reduce hepatic inflammation and improve response to AIH therapy [11,12].